The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and commercialization Early evidence suggests BPC 157 repairs tissue rather than just dulling symptoms. To read more, tap the link in bio. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives